Open AccessAcute myeloid leukemia with t(11;19)(q23;p13.1) in a patient with a gastrointestinal stromal tumor undergoing imatinib therapy: A case report
Author(s) -
Hong Jun Kim,
Sun Kyung Baek,
Chi Hoon Maeng,
Siyoung Kim,
Tae Sung Park,
Ji Sang Han
Publication year - 2020
Publication title -
world journal of clinical cases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.368
H-Index - 10
ISSN - 2307-8960
DOI - 10.12998/wjcc.v8.i7.1251
Subject(s) - medicine , myeloid leukemia , decitabine , imatinib , imatinib mesylate , pancytopenia , gastroenterology , fluorescence in situ hybridization , chromosomal translocation , oncology , stromal tumor , leukemia , bone marrow , cancer research , stromal cell , dna methylation , chromosome , gene , biochemistry , gene expression , chemistry
Acute myeloid leukemia (AML) harboring 11q23 translocations is classified as therapy-related AML in patients who have undergone prior treatment with cytotoxic agents. There have been only a few reports of AML that subsequently developed during imatinib mesylate (IM) treatment for gastrointestinal stromal tumors (GISTs).